Treatment and diagnosis of prostate cancer
AssigneeCornell Research Foundation, Inc.
InventorNeil H. Bander
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed is a hybridoma cell line which produces a monoclonal antibody recognizing antigens of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof.
Claims16
A method of treating, preventing, or delaying development or progression of prostate cancer comprising:
- providing an antibody or antigen binding portion thereof which binds to an antigen expressed on the surface of prostate epithelial cells, said antigen including the epitope bound by an antibody of deposit HB11892, wherein the antibody is an IgG which binds viable cells and wherein the antibody or antigen binding portion thereof is conjugated to a cytotoxic drug;
- and
- administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat, prevent, or delay the development or progression of prostate cancer.
Dependencies are inferred from the claim text.